BR112018014303B1 - Derivados de 3-((hetero-)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano - Google Patents

Derivados de 3-((hetero-)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano Download PDF

Info

Publication number
BR112018014303B1
BR112018014303B1 BR112018014303-0A BR112018014303A BR112018014303B1 BR 112018014303 B1 BR112018014303 B1 BR 112018014303B1 BR 112018014303 A BR112018014303 A BR 112018014303A BR 112018014303 B1 BR112018014303 B1 BR 112018014303B1
Authority
BR
Brazil
Prior art keywords
methyl
phenyl
cis
decan
diazaspiro
Prior art date
Application number
BR112018014303-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112018014303A2 (pt
Inventor
Sven Kühnert
René Michael Koenigs
Anita WEGERT
Paul Ratcliffe
Ruth Jostock
Thomas Koch
Klaus Linz
Wolfgang Schröder
Klaus Schiene
Achim Kless
Ingo Konetzki
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of BR112018014303A2 publication Critical patent/BR112018014303A2/pt
Publication of BR112018014303B1 publication Critical patent/BR112018014303B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112018014303-0A 2016-01-13 2017-01-13 Derivados de 3-((hetero-)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano BR112018014303B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16151013.6 2016-01-13
EP16151013 2016-01-13
PCT/EP2017/025006 WO2017121648A1 (en) 2016-01-13 2017-01-13 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Publications (2)

Publication Number Publication Date
BR112018014303A2 BR112018014303A2 (pt) 2018-12-11
BR112018014303B1 true BR112018014303B1 (pt) 2023-10-03

Family

ID=55129634

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014303-0A BR112018014303B1 (pt) 2016-01-13 2017-01-13 Derivados de 3-((hetero-)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano

Country Status (28)

Country Link
US (6) US20170197947A1 (enExample)
EP (1) EP3402784B1 (enExample)
JP (1) JP6893517B2 (enExample)
KR (1) KR20180098369A (enExample)
CN (1) CN108602777B (enExample)
AR (1) AR107360A1 (enExample)
AU (1) AU2017206909B2 (enExample)
BR (1) BR112018014303B1 (enExample)
CA (1) CA3011177A1 (enExample)
CL (1) CL2018001912A1 (enExample)
CO (1) CO2018008444A2 (enExample)
CY (1) CY1122818T1 (enExample)
DK (1) DK3402784T3 (enExample)
EA (1) EA037481B1 (enExample)
EC (1) ECSP18060848A (enExample)
ES (1) ES2797904T3 (enExample)
HR (1) HRP20200837T1 (enExample)
HU (1) HUE049813T2 (enExample)
IL (1) IL260491B (enExample)
LT (1) LT3402784T (enExample)
MX (1) MX378994B (enExample)
PE (1) PE20181375A1 (enExample)
PL (1) PL3402784T3 (enExample)
PT (1) PT3402784T (enExample)
RS (1) RS60315B1 (enExample)
SI (1) SI3402784T1 (enExample)
TW (1) TWI636048B (enExample)
WO (1) WO2017121648A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6893517B2 (ja) 2016-01-13 2021-06-23 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 3−((ヘテロ−)アリール)−アルキル−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
TWI635082B (zh) 2016-01-13 2018-09-11 歌林達有限公司 3-((雜-)芳基)-8-胺基-2-側氧-1,3-二氮雜-螺-[4.5]-癸烷衍生物
DK3402783T3 (da) 2016-01-13 2020-05-04 Gruenenthal Gmbh 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater
MX378995B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
RS60855B1 (sr) 2016-01-13 2020-10-30 Gruenenthal Gmbh Derivati 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
MX2020010999A (es) 2018-04-18 2021-01-20 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2020144375A1 (en) 2019-01-11 2020-07-16 Grünenthal GmbH Substituted pyrrolidine amides iii
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
IL321707A (en) * 2022-12-28 2025-08-01 Gilgamesh Pharmaceuticals Inc Synthesis of 2-phenyl-2-amino-cyclohexan-1-one history
US20240400537A1 (en) 2023-04-25 2024-12-05 Gruenenthal Gmbh Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
RU2268883C2 (ru) 2001-04-18 2006-01-27 Эро-Селтик, С.А. Аналоги ноницептина и фармацевтическая композиция на их основе
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
PT1519939E (pt) 2002-07-05 2010-02-10 Targacept Inc Compostos n-arildiazaspirocíclicos e métodos para a sua preparação e utilização
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
ZA200510329B (en) 2003-05-23 2007-04-25 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
AU2007312391B2 (en) 2006-10-19 2012-06-21 F. Hoffmann-La Roche Ag Imidazolone and imidazolidinone derivatives as 11b-HSD1 inhibitors for diabetes
EP2150552B1 (en) 2007-04-09 2013-01-02 Janssen Pharmaceutica NV 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
KR20120075500A (ko) * 2008-03-27 2012-07-06 그뤼넨탈 게엠베하 치환된 4-아미노사이클로헥산 유도체
US8268853B2 (en) 2009-06-25 2012-09-18 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
EP3154971A4 (en) 2014-06-13 2017-11-01 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
MX378995B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
JP6893517B2 (ja) 2016-01-13 2021-06-23 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 3−((ヘテロ−)アリール)−アルキル−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
DK3402783T3 (da) 2016-01-13 2020-05-04 Gruenenthal Gmbh 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater
TWI730032B (zh) 2016-01-13 2021-06-11 美商必治妥美雅史谷比公司 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物
TWI635082B (zh) 2016-01-13 2018-09-11 歌林達有限公司 3-((雜-)芳基)-8-胺基-2-側氧-1,3-二氮雜-螺-[4.5]-癸烷衍生物
RS60855B1 (sr) 2016-01-13 2020-10-30 Gruenenthal Gmbh Derivati 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
RU2747877C2 (ru) 2016-01-13 2021-05-17 Ново Нордиск А/С Аналоги эфр(а) с заместителями - жирными кислотами

Also Published As

Publication number Publication date
PL3402784T3 (pl) 2020-09-21
NZ745188A (en) 2024-05-31
CY1122818T1 (el) 2021-05-05
TW201731822A (zh) 2017-09-16
JP6893517B2 (ja) 2021-06-23
WO2017121648A1 (en) 2017-07-20
SI3402784T1 (sl) 2020-07-31
US20200399252A1 (en) 2020-12-24
PT3402784T (pt) 2020-06-18
KR20180098369A (ko) 2018-09-03
EP3402784A1 (en) 2018-11-21
AU2017206909A1 (en) 2018-08-30
RS60315B1 (sr) 2020-07-31
PE20181375A1 (es) 2018-08-28
DK3402784T3 (da) 2020-05-25
HUE049813T2 (hu) 2020-10-28
US20170197947A1 (en) 2017-07-13
JP2019501939A (ja) 2019-01-24
MX2018008644A (es) 2018-11-19
AR107360A1 (es) 2018-04-25
EA037481B1 (ru) 2021-04-01
US10829480B2 (en) 2020-11-10
EP3402784B1 (en) 2020-03-11
CN108602777B (zh) 2022-05-03
MX378994B (es) 2025-03-11
IL260491B (en) 2021-07-29
HRP20200837T1 (hr) 2020-08-07
US20230174520A1 (en) 2023-06-08
AU2017206909B2 (en) 2020-07-09
ES2797904T3 (es) 2020-12-04
US20180327392A1 (en) 2018-11-15
CL2018001912A1 (es) 2018-10-19
US20210179592A1 (en) 2021-06-17
CN108602777A (zh) 2018-09-28
CO2018008444A2 (es) 2018-08-31
LT3402784T (lt) 2020-06-10
BR112018014303A2 (pt) 2018-12-11
EA201891609A1 (ru) 2019-01-31
TWI636048B (zh) 2018-09-21
CA3011177A1 (en) 2017-07-20
ECSP18060848A (es) 2018-08-31
US20200002319A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
EP3402784B1 (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
JP7148660B2 (ja) 3-((ヘテロ-)アリール)-8-アミノ-2-オキソ-1,3-ジアザ-スピロ-[4.5]-デカン誘導体
EP3402783B1 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
BR112018014301B1 (pt) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
BR112018014296B1 (pt) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
HK1260472A1 (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260472B (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK40035886A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260461A1 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260461B (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260528B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260528A1 (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260545A1 (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1260545B (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2017, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2862 DE 11-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.